Use of recombinant viruses to assess the pattern of early human immunodeficiency virus breakthrough infection in the presence of stavudine

References

1. Ahluwalia G. S., Gao W. Y., Mitsuya H., Johns D. G. 1996; 2′,3′-Didehydro-3′-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5′-triphosphate biosynthesis. Molecular Pharmacology 50:160–165
   [Google Scholar]
2. Finzi D., Siciliano R. F. 1998; Viral dynamics in HIV-1 infection. Cell 93:665–671
   [Google Scholar]
3. Gulick R. M., Mellors J. W., Havlir D., Eron J. J., Gonzalez C., McMahon D., Richman D. D., Valentin F. T., Jonas L., Meibohm A. 1997; Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency infection and prior antiretroviral therapy. New England Journal of Medicine 337:734–739
   [Google Scholar]
4. Havlir D., Richman D. D. 1994; Viral dynamics of HIV: implications for drug development and therapeutic strategies. Annals of Internal Medicine 124:984–989
   [Google Scholar]
5. Havlir D. V., Gamst A., Eastman S., Richman D. D. 1996; Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. Journal of Virology 70:7894–7899
   [Google Scholar]
6. Lacey S. F., Larder B. A. 1994; Novel mutation (V75T) in human immunodeficiency virus type I reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrobial Agents & Chemotherapy 38:1428–1432
   [Google Scholar]
7. Lin P. F., Samanta H., Rose R. E., Patick A. K., Trimble J., Bechtold C. M., Revie D. R., Khan N. C., Federici M. E., Li H., Colonno R. J. 1994; Genotypic and phenotypic analysis of human immunodeficiency virus type I isolates from patients on prolonged stavudine therapy. Journal of Infectious Diseases 170:1157–1164
   [Google Scholar]
8. Loveday C., Kaye S., Tenant-Flowers M., Semple M., Ayliffe U., Weller I. D., Tedder R. S. 1995; HIV-1 RNA serum load and resistant viral genotypes during early zidovudine therapy. Lancet 345:820–825
   [Google Scholar]
9. Medina D. J., Tung P. P., Lerner-Tung M. B., Nelson C. J., Mellors J. W., Strair R. K. 1995; Sanctuary growth of human immunodeficiency virus in the presence of 3′-azido-3′-deoxythymidine (AZT. Journal of Virology 69:1606–1611
   [Google Scholar]
10. Medina D. J., Tung P. P., Sathya B., Strair R. K. 1996; Use of floxuridine to modulate the antiviral activity of zidovudine. AIDS Research and Human Retroviruses 12:965–968
    [Google Scholar]
11. Medina D. J., Tung P. P., Nelson C. J., Sathya B., Casareale D., Strair R. K. 1998; Characterization and use of a recombinant retroviral system for the analysis of drug resistant HIV. Journal of Virological Methods 71:169–176
    [Google Scholar]
12. Miller A. D., Rosman G. T. 1989; Improved retroviral vectors for gene transfer and expression. Biotechniques 7:980–990
    [Google Scholar]
13. Mosman T. 1983; Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65:55–63
    [Google Scholar]
14. Najera I., Holquin A., Quinones-Mateu M. E., Munoz-Fernandez M. A., Najera R., Lopez-Galindez C., Domingo E. 1995; Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. Journal of Virology 69:23–31
    [Google Scholar]
15. Page K. A., Landau N., Littman D. R. 1990; Construction and use of a human immunodeficiency virus vector for analysis of viral infectivity. Journal of Virology 64:5270–5276
    [Google Scholar]
16. Perelson A. S., Neumann A. U., Markowitz M., Leonard J. M., Ho D. D. 1996; HIV-1 dynamics in vivo: virion clearance rate, infected cell life span, viral generation time. Science 271:1582–1586
    [Google Scholar]
17. Reed L. J., Muench H. 1938; A simple method for estimating fifty percent end points. American Journal of Hygiene 27:493–496
    [Google Scholar]
18. Strair R. K., Nelson C. J., Mellors J. W. 1991; Use of recombinant retroviruses to characterize the activity of antiretroviral compounds. Journal of Virology 65:6339–6342
    [Google Scholar]
19. Strair R. K., Medina D. J., Nelson C. J., Graubert T., Mellors J. W. 1993; Recombinant retroviral systems for the analysis of drug-resistant HIV. Nucleic Acids Research 21:4836–4842
    [Google Scholar]
20. Wei X., Ghosh S. K., Taylor M. V., Johnson V. A., Emini E. A., Deutch P., Lifson J. D., Bonhoeffer M., Nowak A., Hahn B. H., Saag M. S., Shaw G. M. 1995; Viral dynamics in HIV-1 infection. Nature 373:117–122
    [Google Scholar]
21. Willey R. L., Smith D. H., Lasky L. A., Theodore T. S., Earl P. L., Moss P., Caponi D. J., Martin M. A. 1988; In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. Journal of Virology 62:139–147
    [Google Scholar]
22. Zhang H., Bagasra O., Nikura M., Poiesz B. J., Pomerantz R. J. 1994; Intravirion reverse transcripts in the peripheral blood plasma of human immunodeficiency virus type-1 infected individuals. Journal of Virology 68:7591–7597
    [Google Scholar]